2 / 13
Page 26
Notes:
conferenceseries
.com
Volume 10
Journal of Cancer Science & Therapy
Oncologists 2018
May 24-25, 2018
May 24-25, 2018 Osaka, Japan
22
nd
Global Annual Oncologists Meeting
The histone methyltransferase G9a as a therapeutic target in colorectal cancer
Mei-Ren Pan
Kaohsiung Medical University, Taiwan
N
eo-adjuvant Concurrent Chemo-Radiotherapy (CCRT) is a standard treatment of locally advanced Colon Cancer Cell
(CRC). In order to maximize efficacy and minimize toxicity, new drugs have been developed and used in combination
with CCRT. Recently, it has been shown that G9a plays a role in mediating phenotypes of Cancer Stem Cells (CSCs). This study
aimed to characterize G9a as a biomarker in predicting therapy response to prevent overtreatment and adverse effects in CRC
patients. The primary tumors from 39 patients who received CCRT for rectal cancer were selected. In vivo tumor xenograft
models for tumorigenic properties in immune-deficient mice were developed. In vitro stemness ability was performed by
tumor-sphere assays, cell response to anticancer agents and stemness-related genes analysis. Cells survived from radiation
treatment and displayed high levels of G9a. A significantly positive correlation was shown between G9a and CSCs marker
CD133 in locally advanced rectal cancer patients with CCRT. Knockdown of G9a increased the sensitivity of cells to radiation
treatment and sensitized cells to DNA damage agents through PP2A-RPA axis. Taken together, our study theorized that G9a
might serve as a novel target in colon cancer, which offers exciting potential in prediction of response to preoperative chemo-
radiotherapy in patients with advanced CRC.
Biography
Mei-Ren Pan has completed her PhD from Kaohsiung Medical University, Taiwan. She is currently the Assistant Professor at Graduate Institute of Clinical Medicine,
Kaohsiung Medical University.
mrpan@cc.kmu.edu.twMei-Ren Pan, J Cancer Sci Ther 2018, Volume 10
DOI: 10.4172/1948-5956-C3-130